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ABSTRACT We evaluated the MIC Strip Isavuconazole test against EUCAST E.Def
9.3 by using 40 wild-type and 39 CYP51A mutant Aspergillus fumigatus strains.
The strip full inhibition endpoint (FIE) and 80% growth inhibition endpoint were
determined by two independent readers, reader 1 (R1) and R2. The essential
(within 0, 1, and 2 twofold dilutions) and categorical agreements were best
with the FIE (for R1/R2, 42%/41%, 75%/73%, and 90%/89% for essential agree-
ment, and 91.1%/92.4% categorical agreement, with 6.3/8.9% very major errors
and 0/1.3% major errors, respectively). The MIC Strip Isavuconazole test with the
FIE appears to be useful.
KEYWORDS antifungal susceptibility testing, MIC, isavuconazole, gradient strip,
EUCAST, Aspergillus fumigatus, Cyp51A mutants, wild type
Antifungal susceptibility testing of Aspergillus fumigatus has become increasinglyimportant with the emergence of azole resistance (1–6). EUCAST has set clinical
breakpoints for isavuconazole and Aspergillus (7). For A. fumigatus, the clinical break-
point is 1 mg/liter, one step lower than the epidemiological cutoff value (ECOFF) (2
mg/liter) because the pharmacokinetic/pharmacodynamic breakpoint is 1 mg/liter and
the MIC ranges for wild-type and resistant mutants overlap. Hence an MIC of 2 mg/liter
may represent wild-type isolates as well as isolates with clinically relevant resistance
mechanisms (1–3, 5, 8–15). In clinical practice, the adoption of a restrictive clinical
breakpoint for interpretation of MICs generated by commercial tests may create a
higher risk of misclassiﬁcation unless the susceptibility test is very well standardized
against the reference method and associated with low reader-to-reader and interlabo-
ratory variations. An isavuconazole gradient strip (Etest; AB Biodisk, Solna, Sweden) was
previously evaluated but is no longer available (16, 17). Thus, we evaluated the only
commercially available isavuconazole susceptibility test, the MIC Strip Isavuconazole
test (Lioﬁlchem, Roseto degli Abruzzi, TE, Italy).
Forty wild-type and 39 CYP51A mutant A. fumigatus isolates with hot-spot
alterations involving G54 (n  10), M220 (n  10), TR34/L98H (n  9), and
TR46/Y121F T289A (n  10) were included. For the strip test (Lioﬁlchem, Roseto
degli Abruzzi, TE, Italy) a McFarland 0.5 conidial suspension and RPMI 1640 2%
glucose agar (SSI Diagnostica, Hillerød, Denmark) were used. Strip MICs were read
by two independent technicians (reader 1 [R1] and R2) blind to the CYP51A
genotype at 24 and 48 h of incubation, with an 80% inhibition endpoint (80% IE)
and a full inhibition endpoint (FIE). EUCAST testing was performed as previously
recommended (7, 18). Four control strains were included (see Table S1 in the
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supplemental material) (7). The percent essential agreement between the tests was
calculated. Isolates for which the MICs were above scale by both methods (EUCAST,
16 mg/liter; strip test, 32 mg/liter) were considered in agreement within 0
twofold dilution. The categorical agreement between the methods was calculated
as the percentage of isolates classiﬁed equally by both methods. Very major errors
(VMEs) were deﬁned as isolate categorization as resistant (R) by EUCAST but
susceptible (S) by the strip test, and major errors (MEs) were deﬁned as isolate
categorization as S by the EUCAST method but R by the strip test.
Most isavuconazole strip MICs were above the recommended ranges for the two
control Candida strains (Table S1). In contrast, the strip MICs for A. fumigatus ATCC
204305 and A. ﬂavus CM1813 were within 1 twofold dilution of the EUCAST MICs,
suggesting better agreement for the Aspergillus strains and best when using the FIE for
Aspergillus.
Nine isolates (11.4%) failed to grow sufﬁciently well to allow strip MIC reading on
day 1, when, in general, zones were fuzzy and difﬁcult to read. Day 2 MICs were
lower with the 80% IE than with the FIE (Fig. 1). This was particularly evident for
isolates harboring TR34/L98H alterations, for which the modal 80% IE MICs were 2 and 4
mg/liter, respectively but 32 mg/liter for both readers with the FIE. The essential agree-
ment between the strip MICs from the two readers was highest, 97% at 1 twofold
dilution and 100% at 2 twofold dilutions, when using the FIE (Table 1).
Isavuconazole MICs for isolates with wild-type CYP51A or single alterations at the
G54 codon were all below the EUCAST ECOFF for the strip test with the FIE, as well
as for EUCAST (Table 2). Likewise, the MICs for isolates harboring M220I alterations
or TR34/L98H or TR46/Y121F T289A were all above the clinical breakpoint for both
methods when the FIE was used for the strip test. However, the MICs for TR34/L98H
isolates were higher when determined by the strip test (MIC range, 32 mg/liter)
FIG 1 Isavuconazole strip MICs for wild-type and CYP51Amutant A. fumigatus isolates determined at 80% inhibition (left side) and full inhibition endpoints (right
side) and by two independent readers, R1 (top) and R2 (bottom).
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than when determined by EUCAST (MIC50 of 8 mg/liter; range, 4 to 16 mg/liter)
(Table 2). The overall essential agreement between strip MICs and EUCAST MICs
within 0, 1, and 2 twofold dilutions was best when using the FIE (R1/R2: 42/41,
75/73, and 90/89%) than when using the 80% IE (R1/R2: 25/30, 66/70, and 91/91%). At least
95% essential agreement between the strip test and EUCAST within 2 twofold dilutions
was seen for all CYP51A genotypes except those harboring the TR34/L98H mechanism or
the M220I alteration. Similarly, the categorical agreement was better for the FIE reading of
the strip test (91.1 to 92.4% with 6.3 to 8.9% VMEs and 0 to 1.3% MEs) than for the 80% IE
(89.9%with 10.1% VMEs and 0%MEs for both readers). VMEs included four isolates with the
wild-type CYP51A genotype and one to four isolates harboring M220V, M220I, or G54R
N248K alterations, respectively.
The MIC Strip Isavuconazole test manufacturer recommends an 80% IE reading, but
in this study, higher interreader essential agreement, better separation between wild-
type and resistant strains, and greater essential and categorical agreement compared
to EUCAST results were achieved with the FIE. Thus, the FIE criterion was found to be
superior although the MICs for the recommended Candida control strains were out of
range (7). When using the FIE, the essential agreements with EUCAST within1 and2
twofold dilutions were 73 to 75% and 89 to 90% and thus better than previously found
for the isavuconazole Etest versus the CLSI method, even though challenged here with
a strain collection including a signiﬁcant number of non-wild-type isolates (16). The
categorical agreement was 91% when interpreting the MICs according to EUCAST
breakpoints, and notably, among the 6 to 9% VMEs, half were isolates with a wild-type
CYP51A target gene that either may be harboring other resistance mechanisms or may
be isolates that are truly susceptible but misclassiﬁed as R by the EUCAST reference
method because of the conservative EUCAST susceptibility breakpoint (7). Finally, the
separation between wild-type and TR34/L98H and TR46/Y121F T289A mutant isolates
TABLE 1 Essential agreement between R1 and R2 of MIC Strip Isavuconazole test and between strip and EUCAST MICs
CYP51A proﬁle n
Strip MIC agreement (%)a between
R1 and R2 Agreement (%)a between Strip MIC and EUCAST MIC





R1 80% IE vs
EUCAST
R2 80% IE vs
EUCAST
0b 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2
Wild type 40 55 95 100 83 98 98 38 80 98 28 78 95 18 63 88 15 63 88
G54 alterations
G54E 4 100 100 100 75 100 100 75 100 100 75 100 100 0 100 100 0 75 100
G54R 1 100 100 100 100 100 100 0 0 100 0 0 100 0 0 0 0 0 0
G54V 1 0 100 100 100 100 100 0 100 100 100 100 100 0 100 100 0 100 100
G54W 3 100 100 100 67 100 100 33 100 100 33 100 100 67 100 100 100 100 100
G54R N248K 1 0 100 100 100 100 100 0 100 100 100 100 100 0 100 100 0 100 100
M220 alterations
M220K 3 33 100 100 67 100 100 0 100 100 67 100 100 0 100 100 0 67 100
M220T 2 50 100 100 50 100 100 100 100 100 50 100 100 0 50 100 50 50 100
M220V 2 50 100 100 50 50 100 0 50 100 50 50 100 0 50 100 0 50 50
M220I 2 50 100 100 50 50 100 50 50 50 0 50 50 0 50 100 50 100 100
M220I V101F 1 100 100 100 0 100 100 0 0 100 0 0 100 0 0 0 0 0 100
Mutants with
TRc
TR34/L98H 9 100 100 100 33 78 89 11 11 33 11 11 33 11 22 100 33 67 100
TR46/Y121F
T289A
10 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
All isolates 79 68 97 100 75 94 97 42 75 90 41 73 89 25 66 91 30 70 91
aPercent essential agreement within 0, 1, and 2 twofold dilutions, respectively. MICs were read after 2 days of incubation. Strip MICs were read by using the FIE
or 80% IE endpoint.
bNumber of twofold dilutions.
cTR, tandem repeat in the CYP51A promoter region.
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was greater for the MIC strip test, rendering it a potentially promising routine lab tool
for detecting R environmental mutants, provided the FIE is used (2, 5, 19–21).
The CYP51A amino acid alterations have been associated with a codon-speciﬁc
susceptibility pattern (4, 13). Here, both the strip and EUCAST isavuconazole MICs
indeed straddled the clinical breakpoint for isolates harboring M220 alterations
and for the G54R N24K double mutant, which will inevitably lead to the random
classiﬁcation of such isolates as S or R in routine testing. Hence, as long as clinical
outcome data are unavailable for such mutants, other measures such itraconazole
MIC testing or CYP51A sequencing should be undertaken to detect these genotypes.
This study has limitations. We investigated strip test reader-to-reader agreement but
no other factors associated with variation, such as variation across different lots and
brands of RPMI agar plates, inoculum preparation, etc. Therefore, the promising per-
formance reported here needs conﬁrmation in a multicenter study.
SUPPLEMENTAL MATERIAL
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EUCAST E.Def 9.3 Gradient strip R1 Gradient strip R2
MIC50b MIC range % >ECOFFc % R MIC50b MIC range % >ECOFF % R MIC50b MIC range % >ECOFF % R
Wild type 40 0.5 0.25–2 0 10 0.5 0.125–1 0 0 0.5 0.125–2 0 3
G54 alterations
G54E 4 0.125–0.25 0 0 0.125–0.25 0 0 0.125–0.25 0 0
G54R 1 0.5 0 0 0.125 0 0 0.125 0 0
G54V 1 0.25 0 0 0.125 0 0 0.25 0 0
G54W 3 0.125–0.25 0 0 0.25–0.5 0 0 0.25–0.5 0 0
G54R N248K 1 2 0 100 1 0 0 2 0 100
M220alterations
M220K 3 1–4 33 33 0.5–2 0 33 0.5–1 33 33
M220T 2 0.5–1 0 0 0.5–1 0 0 0.5 0 0
M220V 2 2–4 50 100 1 0 0 1–2 0 50
M220I 2 2–8 50 100 2 to 32 50 100 4 to 32 100 100
M220I V101F 1 16 100 100 32 100 100 32 100 100
Mutants with TRd
TR34/L98H 9 4 to 16 100 100 32 100 100 32 100 100
TR46/Y121F
T289A
10 16 16 100 100 32 32 100 100 32 32 100 100
All isolates 79 1 0.125 to 16 29 38 0.5 0.125 to 32 27 29 0.5 0.125 to 32 29 33
aPlates were read by two independent readers using the FIE endpoint after 2 days of incubation.
bMIC50s (mg/liter) are presented only for genotypes represented by 10 isolates.
cPercentage of isolates with MICs above the EUCAST isavuconazole ECOFF (2 mg/liter) and clinical (1 mg/liter) breakpoints.
dTR, tandem repeat in the CYP51A promoter region.
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